Published in PLoS One on April 23, 2008
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol (2011) 1.89
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood (2011) 1.54
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res (2011) 1.48
Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res (2009) 1.24
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med (2009) 1.13
Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res (2009) 1.11
The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One (2010) 1.09
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol (2009) 1.09
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 1.08
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One (2012) 1.08
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther (2011) 1.07
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One (2012) 1.07
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle (2010) 1.02
Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res (2013) 1.02
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol (2013) 0.99
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res (2011) 0.96
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med (2014) 0.92
Phospholipase A2 inhibits cisplatin-induced acute kidney injury by modulating regulatory T cells by the CD206 mannose receptor. Kidney Int (2015) 0.92
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med (2009) 0.91
In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res (2010) 0.91
Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res (2012) 0.91
Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurg Clin N Am (2010) 0.91
Adoptive cell therapies for glioblastoma. Front Oncol (2013) 0.90
Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicol Appl Pharmacol (2013) 0.90
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med (2010) 0.88
Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci U S A (2010) 0.86
Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia (2012) 0.86
Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. Hum Gene Ther Clin Dev (2013) 0.86
Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. J Neuroinflammation (2010) 0.85
Reciprocal Supportive Interplay between Glioblastoma and Tumor-Associated Macrophages. Cancers (Basel) (2014) 0.82
Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin Dev Immunol (2013) 0.81
Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine. Oncotarget (2015) 0.78
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology (2015) 0.78
Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) (2013) 0.78
Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. Biomed Res Int (2015) 0.78
Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse? Haematologica (2009) 0.77
Naïve rat umbilical cord matrix stem cells significantly attenuate mammary tumor growth through modulation of endogenous immune responses. Cytotherapy (2013) 0.77
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. J Vis Exp (2015) 0.76
PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. Immunotherapy (2014) 0.76
Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cells. Neural Regen Res (2012) 0.76
Immunological Evasion in Glioblastoma. Biomed Res Int (2016) 0.75
Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res (2017) 0.75
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 22.13
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods (1995) 16.00
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol (2006) 14.33
X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet (2001) 10.92
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 6.14
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Cancer immunotherapy: a treatment for the masses. Science (2004) 4.04
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
The IL-2/IL-2 receptor system: a current overview. Cell (1993) 3.33
Primary brain tumours in adults. Lancet (2003) 3.05
What is immune privilege (not)? Trends Immunol (2006) 3.02
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 2.68
Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol (2005) 2.64
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J Immunol (1985) 2.20
Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol (2002) 2.10
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol (2006) 2.10
EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res (2005) 2.02
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev (2006) 2.00
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 1.92
Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature (1985) 1.90
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg (2006) 1.73
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer (2003) 1.63
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2006) 1.47
Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 1.43
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol (2007) 1.35
Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer (2003) 1.35
The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells. Cell Mol Immunol (2006) 1.34
Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol (2006) 1.32
Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol (1998) 1.31
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol (2007) 1.31
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J Immunother (2007) 1.07
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2005) 1.02
Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res (2005) 0.95
Recent advances in immunotherapy for human glioma. Curr Opin Oncol (2006) 0.90
Presence of functional mouse regulatory CD4+CD25+T cells in xenogeneic neonatal porcine thymus-grafted athymic mice. Am J Transplant (2006) 0.89
Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther (2006) 0.86
Cellular immunity and immunotherapy of brain tumors. Front Biosci (2004) 0.82
Regulatory CD4(+)CD25(+) T-cells are controlled by multiple pathways at multiple levels. Int Rev Immunol (2007) 0.79
Glioma-specific antigens for immune tumor therapy. Expert Rev Vaccines (2006) 0.79
An integrated semiconductor device enabling non-optical genome sequencing. Nature (2011) 20.85
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
Meta-analysis of 13 genome scans reveals multiple cleft lip/palate genes with novel loci on 9q21 and 2q32-35. Am J Hum Genet (2004) 2.65
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Loss of function of OsDCL1 affects microRNA accumulation and causes developmental defects in rice. Plant Physiol (2005) 1.77
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Brain edema after intracerebral hemorrhage in rats: the role of inflammation. Neurol India (2006) 1.69
Premature arthritis is a distinct type II collagen phenotype. Arthritis Rheum (2010) 1.66
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
The relationship of hamstrings and quadriceps strength to anterior cruciate ligament injury in female athletes. Clin J Sport Med (2009) 1.55
In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med (2006) 1.52
Hysteroscopic surgery of ectopic pregnancy in the cesarean section scar. J Minim Invasive Gynecol (2009) 1.46
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
Roles of DCL4 and DCL3b in rice phased small RNA biogenesis. Plant J (2011) 1.42
Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol (2006) 1.41
ARGONAUTE10 and ARGONAUTE1 regulate the termination of floral stem cells through two microRNAs in Arabidopsis. PLoS Genet (2011) 1.40
SDG714, a histone H3K9 methyltransferase, is involved in Tos17 DNA methylation and transposition in rice. Plant Cell (2007) 1.39
Arginine methylation mediated by the Arabidopsis homolog of PRMT5 is essential for proper pre-mRNA splicing. Proc Natl Acad Sci U S A (2010) 1.36
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther (2007) 1.36
Comparative analysis of JmjC domain-containing proteins reveals the potential histone demethylases in Arabidopsis and rice. J Integr Plant Biol (2008) 1.35
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 1.33
Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol (2006) 1.32
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol (2007) 1.31
Oryza sativa dicer-like4 reveals a key role for small interfering RNA silencing in plant development. Plant Cell (2007) 1.30
The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol (2005) 1.30
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res (2009) 1.24
GDF5 is a second locus for multiple-synostosis syndrome. Am J Hum Genet (2006) 1.24
Mutations in the Type II protein arginine methyltransferase AtPRMT5 result in pleiotropic developmental defects in Arabidopsis. Plant Physiol (2007) 1.22
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22
AGAMOUS terminates floral stem cell maintenance in Arabidopsis by directly repressing WUSCHEL through recruitment of Polycomb Group proteins. Plant Cell (2011) 1.22
Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther (2005) 1.20
JMJ14 is an H3K4 demethylase regulating flowering time in Arabidopsis. Cell Res (2010) 1.17
Human rhinovirus C infections mirror those of human rhinovirus A in children with community-acquired pneumonia. J Clin Virol (2010) 1.16
Molecular consequences of dominant Bethlem myopathy collagen VI mutations. Ann Neurol (2007) 1.15
Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther (2004) 1.14
The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause (2009) 1.13
ABI4 regulates primary seed dormancy by regulating the biogenesis of abscisic acid and gibberellins in arabidopsis. PLoS Genet (2013) 1.13
Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther (2006) 1.12
WU and KI polyomavirus present in the respiratory tract of children, but not in immunocompetent adults. J Clin Virol (2008) 1.12
The epidemiology and burden of rotavirus in China: a review of the literature from 1983 to 2005. Vaccine (2006) 1.11
In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells. J Immunol (2008) 1.09
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
Epidemiological study of urge urinary incontinence and risk factors in China. Int Urogynecol J (2010) 1.09
ROR1/RPA2A, a putative replication protein A2, functions in epigenetic gene silencing and in regulation of meristem development in Arabidopsis. Plant Cell (2005) 1.09
Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia. Mol Pain (2009) 1.07
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther (2011) 1.07
Human rhinovirus group C infection in children with lower respiratory tract infection. Emerg Infect Dis (2008) 1.06
Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci (2010) 1.05
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther (2008) 1.05